Abstract: Objective: To evaluate the efficacy and safety of tildrakizumab in the treatment of moderate-to-severe plaque psoriasis. Methods: A retrospective analysis was conducted on the clinical data of 32 patients with moderate to severe plaque psoriasis who received treatment with Tildrakizumab in our hospital from February 2024 to November 2024. All patients were administered the drug at week 0 and week 4, followed by once every 12 weeks, with each administration being a 100 mg subcutaneous injection. The PASI and DLQI scores were recorded at weeks 0, 4, and 16. The efficacy and adverse reactions during the treatment process were also monitored. Results: The mean PASI scores of 2 patients at baseline, week 4, and week 16 were 15.68 ± 5.87, 6.48 ± 3.67, and 2.34 ± 5.29, respectively. The PASI improvement rate reached 82.78% ± 38.39% at week 16, with PASI 75, 90, and 100 response rates of 90.63%, 71.88%, and 9.38%, respectively. The DLQI scores were significantly reduced, with a DLQI 0/1 response rate of 37.5% at week 16. There was no significant difference in efficacy between patients with a history of biologic therapy and those without such history. None of the 32 patients experienced serious adverse events. Conclusion: Tildrakizumab has a rapid onset of action in the treatment of moderate-to-severe plaque psoriasis and significant short-term efficacy, with no serious adverse reactions.

Key words: tildrakizumab, moderate-to-severe plaque psoriasis, efficacy, safety